Effectiveness of Ad26.COV2.S vaccine stable for six months
Mar 22, 2022
A single dose of the Johnson & Johnson vaccine was 74% and 81% effective for preventing COVID-19 infection and hospitalizations, respectively, in the U.S. before and during delta variant surge.
Third, fourth COVID-19 vaccine doses boost humoral response in seniors
Jul 27, 2022
Third and fourth doses were tied to significantly increased anti-S IgG titers in older adults, but optimal timing of additional doses is not known.
Last week, the White House said local pharmacies are now providing more than two-thirds of COVID-19 vaccinations.
COVID-19 booster compliance among long-term care workers remains low
By
Kathleen Steele Gaivin
Apr 15, 2022
New Jersey Gov. Phil Murphy (D) this week clarified that long-term care and other healthcare workers in the state satisfy the state’s vaccination requirements once they obtain one booster dose of a COVID-19...
Fourth dose of BNT162b2 offers protection against severe COVID-19
Apr 08, 2022
Protection against COVID-19 did not wane in six weeks after receipt of fourth dose of the Pfizer–BioNTech vaccine; protection against the infection waned.
Third mRNA vaccine dose ups effectiveness against hospitalization
Jan 27, 2022
Vaccine effectiveness against COVID-19 hospitalization is increased with a third dose in those with or without immunocompromising conditions.
COVID-19 infection, vaccination have little effect on migraine worsening
Oct 04, 2023
An increased concern about migraine worsening was a risk factor for perceived migraine worsening.
Republicans coming again for healthcare worker vaccine mandate
By
Jessica R. Towhey
Jan 31, 2023
The Republican-controlled US House of Representatives is expected to vote on two bills today that would have significant effects for long-term care providers.
Pollution tied to risk for serious COVID-19 despite vaccination
Oct 07, 2022
Exposures to PM2.5 and NO2 was linked to increased risk for COVID-19-related hospitalization, with and without adjustment for vaccination.
Plant-based recombinant COVID-19 vaccine found to be effective
May 04, 2022
Vaccine efficacy ranged from 69.5% against symptomatic infection to 78.8% against moderate-to-severe disease.